Advances in B-cell Lymphoma: From Diagnostics to Cure

A special issue of Current Oncology (ISSN 1718-7729).

Deadline for manuscript submissions: 15 June 2025 | Viewed by 1044

Special Issue Editors


E-Mail Website
Guest Editor
Hematology Oncology Division, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Interests: lymphoma; hodgkin's lymphoma; therapy
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
Interests: B-cell lymphoma
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

We are pleased to announce the call for submissions to a Special Issue of the journal Current Oncology, focusing on the topic of advances in B-cell lymphoma. Non-Hodgkin, B-cell lymphomas rank as the tenth most common cancer worldwide, accounting for >60% of all hematopoietic neoplasms. Over the past decade, significant advances have been made regarding the classification, prognostication and treatment of B-cell lymphomas, raising questions about how to best optimize the management of this heterogenous disease. 

This Special Issue aims to provide a comprehensive overview of the current knowledge and advancements in B-cell lymphoma, from its underlying pathology to innovative treatment strategies. We invite the submission of original research articles and reviews that cover various aspects of the management of B-cell lymphoma, including, but not limited to: 

  1. Molecular and genetic profiling of B-cell lymphoma;
  2. Novel biomarkers, prognostic markers and markers of minimal residual disease;
  3. Insights into the tumor microenvironment and immune response;
  4. Targeted therapies and immunotherapies for B-cell lymphoma;
  5. Advances in cellular therapies. 

All submitted articles will undergo a rigorous peer review process to ensure the highest scientific quality and relevance to the field. We encourage contributions from researchers, clinicians and experts in the field of hematopathology, lymphoma research and cellular therapy. 

By consolidating the latest research findings and clinical experiences, we aim to enhance our understanding of the newest advances in lymphoma diagnosis, classification, prognostication and management. We believe that your valuable contributions will significantly contribute to the success of this Special Issue. 

Should you have any questions, require further information or need any assistance, please do not hesitate to reach out to us. 

We look forward to receiving your valuable submissions. 

You may choose our Joint Special Issue in Cancers.

Prof. Dr. Leo I. Gordon
Dr. Megan E. Melody
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • B-cell lymphoma
  • treatment
  • molecular profiling
  • immunotherapies
  • cellular therapies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 2367 KiB  
Communication
Surgical Considerations in Treating Central Nervous System Lymphomas: A Case Series of 11 Patients
by Corneliu Toader, Adrian Vasile Dumitru, Mugurel Petrinel Radoi, Luca-Andrei Glavan, Milena-Monica Ilie, Razvan-Adrian Covache-Busuioc, Vlad Buica, Antonio-Daniel Corlatescu, Horia-Petre Costin, Carla Crivoi and Alexandru Vlad Ciurea
Curr. Oncol. 2024, 31(11), 6659-6672; https://doi.org/10.3390/curroncol31110491 - 25 Oct 2024
Viewed by 810
Abstract
In this retrospective unicentric study, we analyzed the medical records of 11 patients who were surgically treated for CNS lymphoma, both primary and secondary, between 2009 and 2024. Given the rarity of CNS lymphomas and their diverse signs and symptoms based on tumoral [...] Read more.
In this retrospective unicentric study, we analyzed the medical records of 11 patients who were surgically treated for CNS lymphoma, both primary and secondary, between 2009 and 2024. Given the rarity of CNS lymphomas and their diverse signs and symptoms based on tumoral location, our aim was to describe key aspects, such as clinical presentations and surgical management. A possible relationship between obesity and CNS lymphoma progression was investigated through an analysis of previous study findings. The literature suggests a wide spectrum of manifestations, from nausea and headaches to loss of equilibrium and speech impairment. A predominance of unsystematized balance disorders and epileptic seizures were affirmed. Notably, as emerged from our study, aphasia was a particularly interesting neurological symptom due to its rarity in the clinical features of CNSL. Other significant factors, such as tumor localization and perioperative phases, were thoroughly investigated, with the latter highlighted by an illustrative case report. Additionally, a literature review was included, comprising nine recent retrospective studies on the efficacy of surgical resection for patients diagnosed with PCNSL. Full article
(This article belongs to the Special Issue Advances in B-cell Lymphoma: From Diagnostics to Cure)
Show Figures

Figure 1

Back to TopTop